Atrazine interaction with estrogen expression systems.
More than 40 publications have described results of atrazine responses in 17 estrogen-dependent systems and in more than a dozen different reporter and estrogen receptor-binding studies in vitro. Results from these studies have consistently failed to demonstrate that atrazine acts as an estrogen agonist. Moreover, a variety of indices of estrogen-dependent activity, in models that encompass cell incubations to whole animals, have failed to respond to atrazine. Researchers in more than a dozen laboratories have examined rats, rat tissues, human and prokaryotic cells, in addition to tissues from reptile, fish, amphibian, avian, molluscan, and insect sources, without eliciting estrogenic-like responses from atrazine. In contrast, studies of atrazine ability to antagonize estrogen-mediated responses have yielded equivocal results. Results of several studies show inhibition of estrogen-like activities by atrazine, yet many other tests have yielded negative results. Generally, in vivo models have more consistently shown that atrazine inhibits estrogen-mediated responses, whereas in more specific in vitro systems, inhibition is seldom observed. The implication is that in vivo effects of atrazine may result from inhibition of factors that are indirectly connected to the genomic interaction of estrogen (e.g., at the receptor). Potential targets of atrazine may be downstream of the ligand-receptor binding event. Atrazine may also interact with other, less specific, factors that are necessary for the completion of the estrogen-mediated response. Moreover, the apparent inhibition of cytosolic-ER binding by atrazine may, similarly, be relatively nonspecific. Observed inhibitory responses occur only at extreme doses or concentrations, i.e., several orders of magnitude greater than the level of estradiol presence in each test system. It is probable that the inhibitory effects result from very low affinity and/or low specificity interactions, which are unlikely to occur in nature. We conclude that atrazine is not an estrogen receptor agonist, but it may be a weak antagonist, when present at a high concentration under conditions of disequilibrium with estrogen. These conditions are not expected to occur as a result of normal environmental exposure.
Eldridge
J Charles
JC
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1083, USA. eldridge@wfubmc.edu
Stevens
James T
JT
Breckenridge
Charles B
CB
D000818:Animals; D001280:Atrazine / Q000633:toxicity*; D004967:Estrogens / Q000502:physiology*; D006540:Herbicides / Q000633:toxicity*; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D011960:Receptors, Estrogen / Q000378:metabolism
D004967:Estrogens; D006540:Herbicides; D011960:Receptors, Estrogen; D001280:Atrazine